Patient characteristics
| Characteristic . | Sensitive to ABT-737 (N = 33) . | Resistant/intermediate to ABT-737 (N = 24) . | P . | ||
|---|---|---|---|---|---|
| No. (%) . | Value (range) . | No. (%) . | Value (range) . | ||
| Median age, y (range) | 66.5 (48-87) | 61.0 (50-77) | .53 | ||
| Sex, male/female | 26 (78.8) | — | 19 (79.1) | — | 1.0 |
| 7 (21.2) | — | 5 (20.8) | — | ||
| Treatment for CLL before ABT-737 testing | 10 (30.3) | — | 8 (33.3) | — | 1.0 |
| FISH | |||||
| 17p | 2 of 14 (14.3) | — | 2 of 11 (18.2) | — | 1.0 |
| 11q | 4 of 14 (28.6) | — | 2 of 11 (18.2) | — | .66 |
| 13q14 | 8 of 14 (57.1) | — | 7 of 11 (63.6) | — | 1.0 |
| Trisomy 12 | 2 of 13 (15.4) | — | 1 of 10 (10) | — | 1.0 |
| 13q34 | 1 of 13 (7.7) | — | 3 of 11 (27.3) | — | .30 |
| Characteristic . | Sensitive to ABT-737 (N = 33) . | Resistant/intermediate to ABT-737 (N = 24) . | P . | ||
|---|---|---|---|---|---|
| No. (%) . | Value (range) . | No. (%) . | Value (range) . | ||
| Median age, y (range) | 66.5 (48-87) | 61.0 (50-77) | .53 | ||
| Sex, male/female | 26 (78.8) | — | 19 (79.1) | — | 1.0 |
| 7 (21.2) | — | 5 (20.8) | — | ||
| Treatment for CLL before ABT-737 testing | 10 (30.3) | — | 8 (33.3) | — | 1.0 |
| FISH | |||||
| 17p | 2 of 14 (14.3) | — | 2 of 11 (18.2) | — | 1.0 |
| 11q | 4 of 14 (28.6) | — | 2 of 11 (18.2) | — | .66 |
| 13q14 | 8 of 14 (57.1) | — | 7 of 11 (63.6) | — | 1.0 |
| Trisomy 12 | 2 of 13 (15.4) | — | 1 of 10 (10) | — | 1.0 |
| 13q34 | 1 of 13 (7.7) | — | 3 of 11 (27.3) | — | .30 |
P values are indicated based on using Fisher exact test (categorical variables) or the Student t test (continuous variables).
— indicates not applicable; and FISH, fluorescence in situ hybridization.